2013 Pharma and Biotech Financial Report - Pharmaceutical Executive

ADVERTISEMENT

2013 Pharma and Biotech Financial Report


Pharmaceutical Executive


Biotech stocks—on the up

Against a backdrop of strong general market performance, the Y&P Large Cap Biotech, Y&P Mid Cap Biotech, and Y&P Small Cap Biotech Indices did exceptionally well in the first three quarters of this year, increasing by 58 percent, 68 percent and 161 percent, respectively. This is a continuation of their strong performance last year.

Equity markets have fallen in love with the biotech industry again. With relatively low market float, modest to moderate movements of capital into the biotech sector have caused significant increases in the price of shares as investors have searched for growth areas to invest in.

For some time, market sentiment towards the biotech industry was decidedly mixed, except for established biotech companies and companies with positive late stage data. But the sentiment changed last year and continues this year.

Biotech M&A—consistently modest

Given the perception that Big Pharma needs to fill its product pipeline, Biotech M&A activity has been chronically modest for the last couple of years, with just a few exceptions.

In the first three quarters of 2013 there were 21 biotech M&A deals completed worth $6 billion. This compares to 19 deals worth $19.7 billion for all of 2012. Dollar volume has fallen, but the number of deals has increased. The dollar volume decrease was largely due to Gilead's acquisition of Pharmasset in 2012 for $10.4 billion. But it was not the only large deal last year. Dainippon Sumitomo acquired Boston Biomedical for $2.6 billion and BMS acquired Inhibitex for $2.1 billion.

The reduced number of large deals is partly due to the very high stock market valuations and the bidding up of prices for late stage biotech companies which has dampened the pharma company pursuit of certain biotech companies. Also, for much of this year biotech companies have had an attractive IPO climate as the alternative to a sale option.

Although pharma and biotech executives believe that there should be a great deal of M&A activity, pharma companies are accomplishing many of their strategic goals using other alternatives to M&A such as licensing and partnering.

Interestingly, earn-outs have become a major portion of transactions this year, featuring in 13 of the 21 deals completed. Although earn-outs or "structured acquisitions" involving contingent payments have been common in biotechnology M&A deals, they peaked in 2011 and fell to 32% of biotech deals completed last year. This has changed dramatically thus far in 2013, surging to 62%. The primary reason has been an increased need to bridge the value gap between buyer and seller.

Interestingly, as of September 30, the value of deals announced but not closed was only $500 million (with one deal). This suggests continued weakness looking forward in biotech M&A volume.

Gains in biotech financing

Debt financing has been close to a standstill. Only $492 million of non-bank debt was issued in the first three quarters of 2013 compared to $794 million for all of 2012. This is a continuation of an almost non-existent debt financing market for a number of years.

Equity issuance volume in the first three quarters of 2013 was much stronger, with 78 offerings worth $5.9 billion compared to 85 offerings worth $5.6 billion for all of 2012. This puts the industry ahead of last year's pace in terms of both number of deals and dollar volume.


Biotech IPOs
The IPO market has become exceptionally strong recently with a surging stock market and very positive biotech stock price performance. First three quarters 2013 issuance includes 29 biotech IPOs totaling $2 billion. This is a huge increase over the 13 IPOs in 2012 and the 6 in 2011.

Although there have always been long periods between the periodic biotech IPO frenzy that happens from time to time, this time around the inactive period was particularly long. The real question will be how long this peak period lasts. At least in the past, the peak periods have been relatively short.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here